Bioventus stock
BVSNASDAQBioventus Inc., HealthcareISIN US09075A1088
61Score 61 out of 100, Neutral
Price and trend
49 / 100
Price history
+43% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 0.4% below it.
Since December 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 21).
The price is 28% below its 52-week high. Largest decline in 6 years: 95% (February 2021 to May 2023).
Chart figures for advanced users
- SMA 50$13.28
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.03
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)21
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.53
- The lowest closing price of the last twelve months.
- Resistance$15.26
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Bioventus Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $752.53M, is number 69 of 90 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $597.59M (up 5.2%) and adjusted earnings per share of $0.77 (up 12.9%).
- MEQIRI Score 61 out of 100 (Neutral): rank 259 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $26.98, with the price 59% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 59% below the fair value of $26.98.Valuation 96
- Earnings turn into cashFree cash flow 148% of earnings over the last 12 months.Fundamentals 55
Weaknesses
- DilutionShare count up 77% since 2020.Capital allocation 45
- Interest barely coveredOperating profit covers interest only 2 times.Stability 49
- Volatile share priceVolatility 53% a year over the last 12 months.Stability 49
Its standout strengths are valuation and growth, while stability and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 62 to 61.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $19.27 and expensive above $44.96 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $22.49, at 8.3% it would be $33.49.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 26 Sep 2026, revenue rose 3.9% on the twelve months before. Revenue has grown solidly since 2013, at about 8% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 67%, operating 10%, net 4%. Last 12 months: net 10%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Mar 2027in 112 days
- Last reported
- 2 Nov 2026EPS reported $0.17 (expected $0.15)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 3.5% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.77−1.4%
- Revenue
- $597.59M−1.2%
- Earnings per share
- $0.89−3.5%
- Revenue
- $635.33M−1.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +4.2%2026 guidance reiterated on all metrics, strong double-digit growth expected in the second half.
“Rob will provide an update on our 2026 priorities and the second quarter highlights, and then Mark will review second quarter results and discuss our 2026 financial guidance.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Bioventus
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 61
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- InModeINMD $790.08M72
- Varex ImagingVREX $780.9M53
- Delcath SystemsDCTH $757.34M64
- Cytek BiosciencesCTKB $753.32M47
- Synektik Spólka AkcyjnaSNT.WA $709.44M77
- Senseonics HoldingsSENS $684.97M44
- Xvivo PerfusionXVIVO.ST $653.35M50
- Pacific Biosciences of CaliforniaPACB $649.64M38
ETFs that hold Bioventus
Held by 3 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.04% | 0.39% | €1.47B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 26 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.